Top-News

VolitionRX Aktie News

Aktie
WKN:  A12B6K ISIN:  US9286611077 US-Symbol:  VNRX Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
0,3252 $
+0,0138 $
+4,43%
0,27935 € 18:34:13 Uhr
Depot/Watchlist
Marktkapitalisierung *
30,66 Mio. €
Streubesitz
62,49%
KGV
-1,94
Index-Zuordnung
-

VolitionRX News

07.05.25 - PR Newswire
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption PR Newswire
31.03.25 - PR Newswire
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update PR Newswire
28.03.25 - PR Newswire
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025 PR Newswire
27.03.25 - PR Newswire
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 PR Newswire
26.03.25 - PR Newswire
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering PR Newswire
25.03.25 - PR Newswire
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update PR Newswire
21.03.25 - PR Newswire
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-​Billion Dollar Liquid Biopsy Industry PR Newswire
20.03.25 - PR Newswire
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer PR Newswire
17.03.25 - PR Newswire
Volition Proudly Sponsors the 44th ISICEM Congress
Volition Proudly Sponsors the 44th ISICEM Congress PR Newswire
13.03.25 - PR Newswire
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems PR Newswire
11.03.25 - PR Newswire
Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test PR Newswire
04.03.25 - PR Newswire
Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time
Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time PR Newswire
28.02.25 - PR Newswire
Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference
Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference PR Newswire
06.02.25 - PR Newswire
Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
Volition Signs First Commercial Project Utilizing Rapid High-​Throughput Model in the Study of NETosis PR Newswire
05.02.25 - PR Newswire
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025 PR Newswire
30.01.25 - PR Newswire
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis PR Newswire
08.01.25 - PR Newswire
Volition Issues Business Review 2024
Volition Issues Business Review 2024 PR Newswire
12.12.24 - PR Newswire
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants PR Newswire
10.12.24 - PR Newswire
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening PR Newswire
06.12.24 - PR Newswire
VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering
VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +2,17%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »